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Breast cancer stem cells rely on fermentative
glycolysis and are sensitive to 2-deoxyglucose
treatment
D Ciavardelli*,1,2, C Rossi2,3, D Barcaroli2,3, S Volpe4, A Consalvo2,3, M Zucchelli2,3, A De Cola2,3, E Scavo4, R Carollo4,
D D’Agostino2,3, F Forlı`2,3, S D’Aguanno5, M Todaro4, G Stassi4, C Di Ilio3, V De Laurenzi*,2,3,7 and A Urbani5,6,7
A number of studies suggest that cancer stem cells are essential for tumour growth, and failure to target these cells can result in
tumour relapse. As this population of cells has been shown to be resistant to radiation and chemotherapy, it is essential to
understand their biology and identify new therapeutic approaches. Targeting cancer metabolism is a potential alternative
strategy to counteract tumour growth and recurrence. Here we applied a proteomic and targeted metabolomic analysis in order
to point out the main metabolic differences between breast cancer cells grown as spheres and thus enriched in cancer stem cells
were compared with the same cells grown in adherent differentiating conditions. This integrated approach allowed us to identify
a metabolic phenotype associated with the stem-like condition and shows that breast cancer stem cells (BCSCs) shift from
mitochondrial oxidative phosphorylation towards fermentative glycolysis. Functional validation of proteomic and metabolic data
provide evidences for increased activities of key enzymes of anaerobic glucose fate such as pyruvate kinase M2 isoform, lactate
dehydrogenase and glucose 6-phopshate dehydrogenase in cancer stem cells as well as different redox status. Moreover, we
show that treatment with 2-deoxyglucose, a well known inhibitor of glycolysis, inhibits BCSC proliferation when used alone and
shows a synergic effect when used in combination with doxorubicin. In conclusion, we suggest that inhibition of glycolysis may
be a potentially effective strategy to target BCSCs.
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One of the main problems in the therapy of breast tumour is
long-term relapse. This can in part be explained by failure to
eradicate a subset of cells within the tumour that are then
capable of sustaining tumour growth. These cells share a
number of features with stem cells and have therefore been
called cancer stem cells (CSCs). CSCs have been isolated
from a variety of solid tumours, including breast cancer1 and
appear to have role in resistance to treatment as well as in
metastasis formation.2 Indeed, CSCs present several intrinsic
mechanisms of resistance to conventional antitumour drugs
and radiation therapy such the overexpression of adenosine
triphosphate (ATP)-binding cassette (ABC) drug transporters,
activation of survival pathways, increased production of anti-
apoptotic factors, higher defences against oxidative stress,
and efficient repair of DNA damage.3 Therefore the
development and validation of new therapeutic strategies
targeting CSCs is urgently needed to improve clinical
outcome.
Recently, the interest on studying cancer metabolism and
the so called Warburg effect has grown as targeting specific
metabolic pathways might be a promising approach to cancer
therapy.4,5 Warburg effect defines cancer dependence on
fermentative glycolysis allowing for the diversion of key
metabolites into cellular biosynthetic pathways in proliferating
cancer cells,6 including CSC, and it has been suggested that it
can be exploited to develop new pharmacological treatments
that can counteract the chemo-resistance of these cells.7,8
It has also been suggested that metabolic changes may
have a causal role in inducing different phenotypic states of
cancer cells. As an example, Dong et al.9 have shown that
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silencing of the gluconeogenic enzyme fructose-1,6-bipho-
sphatase that activates fermentative glycolysis results
in a stem-like phenotype. Despite their importance, the
metabolic features of CSCs still remains largely unknown.
Recently, it has been shown that CSCs isolated from several
solid tumours display significant alteration of energy metabo-
lism and are more glycolytic compared with more differen-
tiated tumour cells10–13or normal stem cells.14 However, this
is still a controversial issue as previous studies have shown
that CSCs are less glycolytic than the differentiated ones.15
Here, using an integrated proteomic and targeted meta-
bolomic approach, we show that the metabolism of breast
cancer stem cells (BCSCs) grown as spheres is strongly
linked to fermentative glycolysis comparedwith the same cells
grown in adherent differentiating conditions (spheroid-derived
adherent cells (SDACs)). On the basis of these evidences, we
sought to test the effect of a well-characterized glycolytic
inhibitor, 2-deoxy-D-glucose (2-DG),16,17 alone or in combi-
nation with the widely used chemotherapeutic doxorubicin
(Doxo) on BCSCs’ growth and proliferation. Our results
indicate that BCSCs are highly sensitive to 2-DG that also
shows a synergic effect with Doxo treatment.
Results
Differential proteomics analysis indicates a shift toward
fermentative glucose metabolism in BCSC spheres. In
this study, we have analysed differential protein expression
profiles of BCSCs and SDACs. As previously reported,18 the
in vitro model adopted for differentiated cells, conventionally
reported as SDACs, relies on sphere cells cultured in
Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) in adherent conditions.
These cells express higher levels of cluster of differentiation
24 (CD24) as expected for SDACs (Supplementary
Figure S1).19,20
Compared with the gel electrophoresis-mass spectrometry
(GC–MS) proteomics approach, label-free liquid chromato-
graphy tandem mass spectrometry (LC-MS/MS) provides a
high throughput and low expensive analytical method for
characterization of complex protein mixtures with suitable
sensitivity and repeatability. Protein identification, quantifica-
tion, and data quality of exact mass retention time clusters
(EMRTs), which are the recorded mass species associated to
their exact masses and retention times, were evaluated.
A total of 39 379 and 39 379 EMRTs were determined for the
comparison of BCSCs grown as spheres versus SDACs for
3.5 and 7 days, respectively. For each replicate conditions,
the distribution of mass error was under 15 p.p.m. (Figures 1a,
d and g for BCSCs and SDAC collected after 3.5 days and
7 days, respectively), the intensity coefficient of variation
expressed as percentage (% CV intensity) had a Gaussian
distribution with all values o4.5% (Figures 1b, e and h for
BCSCs and SDAC collected after 3.5 days and 7 days,
respectively) and the retention time coefficient of variation
expressed as percentage (% CV RT) waso10% (Figures 1c,
f and i for BCSCs, SDAC collected after 3.5 days and 7 days,
respectively) with most of the species o5%. Applying
the stringent criteria of protein identification and
quantification described in the Materials and Methods, we
identified 54 and 28 proteins differentially expressed in
BCSCs compared with SDACs collected after 3.5 and 7 days
in differentiating conditions. The lists of differential
proteins are shown in Supplementary Tables S1 and S2,
while the details of peptide identifications are reported in
Supplementary Tables S3 and S4.
Venn analysis (Figure 1j) shows that 19 proteins were
upregulated in spheres as compared with both time points of
differentiation, whereas 5 were downregulated in the same
experimental conditions. Interestingly, the expression levels
of these proteins did not change between 3.5 and 7 days in
adherent conditions (Figure 1k), thus suggesting that the
differences were strictly related to the stem-like condition. We
therefore decided to use SDACs collected after 3.5 days in
adherent conditions for all the subsequent studies, thereby
focusing on early changes between the BCSC and SDAC
condition.
Bioinformatic analysis of these differentially expressed
proteins identified two significant overlapping protein networks
related to the haematological, immunological, and infla-
mmatory diseases (score¼ 62) and the free radical scaven-
ging and cancer pathway (score¼ 3) (Figures 2a and b).
Functional analysis based on GO terms indicated that
several of the differentially expressed proteins are strictly
related to glycolysis (P¼ 3 10 13) and gluconeogenesis
(P¼ 2 10 8) (Figure 2c). In particular, the increased
expression levels of key enzymes of fermentative glycolysis
such as pyruvate kinase M2 (PKM2) and lactate dehydro-
genase A (LDH-A) in spheres compared with SDACs might
indicate that spheres essentially metabolize glucose
through a non-oxidative pathway even under normoxic
conditions. This hypothesis is in line with the reported
upregulation of hypoxia-inducible factor 1a (HIF-1a) in
CSC12,21 and with the predicted activation of HIF-1a-
dependent pathway as suggested (z-score¼ 2.791) by the
higher expression in BCSC as compared with SDACs of
several proteins involved in this pathway such as triose-
phosphate isomerase 1, phosphoglycerate kinase 1, galectin 1,
LDH-A, heat-shock 70-kDa protein, glyceraldheyde 3-phos-
phate dehydrogenase, enolase 1, and aldolase A. Indeed,
Figure 1 Data quality evaluation, Venn analysis, and expression ratios for significantly regulated proteins in BCSCs compared with SDACs. Analytical reproducibility of
mass spectra was assessed in BCSCs, and cells were allowed to differentiate as SDACs for 3.5 and 7 days. Bar charts show the mass relative standard deviation (RSD) and
the intensity and retention time coefficients of variation (% CV) of exact mass retention time clusters detected in BCSCs (a, b, c), and SDACs collected at 3.5 days (d, e, f) and
7 days (g, h, i) post-differentiation (pd). (j) Four-way Venn diagram analysis of differentially expressed proteins identify 15 loci. Numbers in parentheses represent the total
number of identified proteins clustered in each locus. BCSCs compared to SDACs 3.5 days pd show 25 and 5 proteins specifically up-regulated and down-regulated,
respectively; BCSCs show 4 proteins up-regulated compared to SDACs 7 days pd; BCSCs show 19 and 5 proteins up-regulated and down-regulated, respectively compared
to SDACs regardless of differentiation time. The Swiss-Prot accession numbers are listed in table (see the Supplementary Tables S1 and S2 for a detailed description).
Analysis was performed using the four-way Venn Diagram Generator freely available at http://www.pangloss.com/seidel/Protocols/venn4.cgi. (k) Bar chart displays the mean
protein expression level ratios (n¼ 3) of 19 and 5 proteins up- and down-regulated, respectively in BCSCs compared to SDACs regardless of differentiation time . The red line
indicates the expression ratio¼ 1
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a western blotting (WB) analysis confirms that BCSCs
express higher levels of HIF-1a as compared with SDACs
(Figure 2d).
Targeted metabolomics shows increased lactic
fermentation rate and inhibition of fatty acid (FA)
beta-oxidation in BCSCs. In order to verify whether
BCSCs were more glycolytic when grown as spheroids than
when grown as SDACs, we performed targeted metabolomic
analysis of glycolysis intermediates. We found that levels of
fructose 1,6-diphospate, pyruvate, lactic acid, and ribose 5-
phosphate were significantly higher in BCSCs (Figure 3a,
Supplementary Table S5). In addition, we did not find
significant differences in concentrations of Krebs cycle
intermediates with exception of succinic acid, which was
significantly higher in BCSCs (Figure 3a, Supplementary
Table S5), and fumaric acid, which was higher in BCSCs, but
the difference with SDACs was not statistically significant
(mean±S.D.¼ 1995±257 and 1233±638ng/mg 1 in
BCSCs and differentiated cells, respectively; P¼ 0.204).
Our data also indicate relevant alterations of acylcarnitines
(AcCs) and amino acids (AA) profiles in BCSCs. The
concentrations of valine (Val), ornitine, phenylalanine,
arginine (Arg), tyrosine, serine, histidine (His), proline,
glycine (Gly), and lysine/glutamine increased in BCSCs as
compared with SDACs (Figure 3b; Supplementary Table
S5). Both Lys and Gln are undistinguishable by LC-MS/MS,
and we have been able to assess their overall concentration.
In contrast, alanine (Ala) significantly decreased in
BCSCs compared with SDACs (Figure 3b; Supplementary
Table S5).
Of note, we found a significant lower levels of free carnitine
in spheres as compared with SDACs (Figure 3b,
Supplementary Table S5), suggesting the inhibition of AcCs
synthesis and finally of FA beta-oxidation. Consistently with
this hypothesis, short, medium, and long-chain AcCs were
undetectable in BCSCs. In contrast, AcCs were all quantifi-
able in SDACs (Supplementary Table S5).
BCSCs show higher activity of key enzymes of
anaerobic glucose metabolism. We further validated the
expression level of PKM2 and LDH-A, key enzyme of aerobic
glycolysis, by WB analysis of protein extracts collected from
BCSCs and SDACs. We confirmed that PKM2 and LDH-A
were significantly upregulated in BCSCs compared with
SDACs (Figure 4a, P¼ 0.008 and 0.034, respectively; n¼ 3).
Furthermore, BCSCs displayed increased PK (mean±
S.D.¼ 2.5±0.7 and 1.0±0.2 mmol/mgProtein/min in BCSCs
and SDACs, respectively; P¼ 0.0001; n¼ 6) and LDH-A
(mean±S.D.¼ 2.0±0.8 and 1.3±0.1mmol/mgProtein/min in
Figure 2 Functional and protein network analysis indicates increased glycolytic activity and activation of HIF-1a pathway in BCSCs. Ingenuity Pathway Analysis of
differentially expressed proteins in BCSCs compared with SDACs result in two interaction network related to (a) the haematological, immunological, and inflammatory
diseases and (b) the free radical scavenging and cancer pathway. Diagrams show focus genes (the differentially expressed proteins) that are depicted in green
(downregulated) or red (upregulated). Solid and dashed lines indicate the direct and indirect interactions, respectively, and the arrows indicate the modulatory role of proteins
or endogenous chemicals. (c) The canonical pathways associated with BCSCs are glycolysis, gluconeogenesis, and superoxide radical degradation. Functional pathway
analysis was performed using the Ingenuity Pathway Analysis tool for the significantly regulated proteins in BCSCs compared with SDACs. The bar graph shows the scores
( log10P) associated to the pathways enriched with regulated proteins as determined using right-tailed Fisher’s exact test with thresholdo0.050. The yellow line indicates
the ratio calculated as the number of proteins in a given pathway that meet the cutoff criteria (P¼ 0.050) divided by the total number of molecules that make up that pathway.
(d) BCSCs upregulate normoxic HIF-1a. Nuclear extracts were assessed for HIF-1a and laminin b by WB. WB shows that the HIF-1a expression level significantly decreases
in cells allowed to differentiate as SDACs for 3.5 days
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BCSCs and SDACs, respectively; P¼ 0.044; n¼ 6) activity
(Figures 4b and c).
In order to confirm that the metabolic differences observed
are indeed due to differences between CSCs and more
differentiated cancer cells, we sorted CD24 /low cells within
the sphere culture, supposed to be the less differentiated
more stem-like cells, and compared them with a more
differentiated population expressing higher CD24 levels. We
assessed the expression levels and enzymatic activities of
LDHandPK in CD24 /low andCD24þ BCSCs. In accordance
with a more glicolitic phenotype, CD24 /low cells show higher
levels (Figure 4d) and activities of PK (mean±
S.D.¼ 19.2±0.3 and 2.0±0.4mmol/mgProtein/min in CD24 /low
and CD24þ cells, respectively; P¼ 6 10-13; n¼ 6) and LDH
(mean±S.D.¼ 3.6±0.3 and 2.5±0.5mmol/mgProtein/min in
CD24 /low and CD24þ cells, respectively; P¼ 0.002; n¼ 6)
(Figures 4e and f) as compared with CD24þ cells.
Glucose 6-phosphate dehydrogenase (G6PDH) is the key
enzyme of pentose phosphate pathway, the metabolic
process providing NADPH to the cells that is required for
anabolic pathways. Our proteomic data also show that
G6PDH is more expressed in BCSCs although the difference
with SDACs is not statistically significant (data not shown).
Indeed by WB analysis, we show that G6PDH is upregulated
in spheres compared with SDACs (P¼ 0.036; n¼ 3;
Figure 4a), and its activity is significantly increased
(mean±S.D.¼ 2.3±0.8 and 1.2±0.3mmol/mgProtein/min in
BCSCs and differentiated cells, respectively;P¼ 0.004; n¼ 6;
Figure 4g). According to the increase of G6PDH expression
and activity, we found a decreased NADPþ /NADPH ratio
in spheres (mean±S.D.¼ 0.94±0.05 and 1.063±0.004 in
BCSCs and SDACs, respectively; P¼ 0.013, Figure 4h).
These results suggest increased biosynthesis of NADPH
through the pentose phosphate pathway in BCSCs compared
with SDACs.
BCSCs show increased reduced nicotinamide adenine
dinucleotide (NADH) consumption and cytosolic ATP
production. Adenosine diphosphate (ADP)/ATP and
NADþ /NADH ratios are indices of aerobic or anaerobic energy
metabolism, cellular energy turnover, and redox cellular state.
We found that NADþ /NADH ratios are significantly higher in
BCSCs compared with SDACs (mean±S.D.¼ 11.9±0.6 and
6.7±0.3 in BCSCs and differentiated cells, respectively; P¼ 2
 10 4, Figure 4i). This is associated with the increase of
NADH consumption and decreased NADþ production in
BCSCs. In fact, NADH concentrations (mean±S.D.¼
0.06±0.04 and 0.13±0.02mmol/l in BCSCs and SDACs,
respectively; P¼ 0.050) as well as NADþ levels
(mean±S.D.¼ 0.73±0.04 and 0.88±0.07mmol/l in BCSCs
and SDACs, respectively; P¼ 0.045) significantly decrease in
BCSCs compared with SDACs.
BCSCs also show an increased ADP/ATP ratio
(mean±S.D.¼ 0.23±0.03 and 0.15±0.06 in BCSCs and
differentiated cells, respectively; P¼ 0.016, Figure 4j).
Of note, we found that treatment with rotenone, an
uncoupling agent of the electron transport chain (ETC),
increases the ADP/ATP ratio in SDACs (mean±
S.D.¼ 0.13±0.02 and 0.247±0.006 for control and SDACs
treated with rotenone, respectively; P¼ 0.001), while it has no
effect on the ATP production in BCSCs (mean±
S.D.¼ 0.21±0.02 and 0.20±0.01 for control and BCSCs
treated with rotenone, respectively; P¼ 0.732). These find-
ings suggest that uncoupling of ETC markedly inhibits ATP
Figure 3 Targeted metabolomics reveals significant alterations of glycolytic intermediates, glucose-derived non-essential amino acids, free carnitine, and AcCs,
suggesting increased lactic fermentation and inhibition of FAoxidation in BCSCs. Bar graphs show the mean concentrations of (a) glycolytic and Krebs cycle intermediates and
(b) amino acids and free carnitine in BCSCs and SDACs. Results of targeted metabolomic analysis are available in the Supplementary Table S5. The differences shown in the
bar graphs are all significant (two-tailed t-test, Po0.050). Concentrations are expressed as ng/mg (wet weight). Bars show the mean value±S.D. (n¼ 6)
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production in SDACs but not in BCSCs that rely on lactic
fermentation (Figure 4j).
2-deoxyglucose (2-DG) inhibits BCSCs’ growth and
survival. Overall, our data indicate that BCSCs display an
anaerobic metabolic phenotype compared with SDACs.
Therefore, we tested the effect, on BCSCs’ growth and
survival, of 2-DG, a compound known to inhibit the first phase
of glycolysis, alone or in combination with Doxo, a chemother-
apeutic agent used for the treatment of breast cancer.
Our results show that Doxo exerts a cytostatic effect on
BCSCs but a very modest, if any, toxic effect (Figures 5a and b).
Notably, BCSCswere substantially blocked in theG2 phase of
cell cycle (data not shown). In contrast, 2-DG provides a
significant time-dependent cytotoxic effect inducing up to 44%
apoptosis after 48 h of treatment (Figure 5b).
Interestingly, the combination of 2-DGwith Doxo results in a
higher cytotoxic effect compared with the treatment with Doxo
alone or 2-DGalone after 2 days reaching 80%apoptosis after
48 h (Figure 5b). As expected, more differentiated cells are
more responsive to Doxo; however they appear less sensitive
to 2-DG than BCSCs (Figure 5c). This is in line with a less
glycolityc metabolism. Again, the combined treatment results
in a much higher response also in SDACs (Figure 5c).
Discussion
Growing evidence show that a subset of cancer cells, known
as CSCs, are key drivers of tumour progression, being the
clonogenic population that supports tumour growth. Accord-
ing to the CSC model, failure to eradicate these cells with
current therapies can result in tumour recurrence. As these
Figure 4 The expression levels and activities of glycolytic enzymes are increased in BCSCs and correlate with altered energy and redox status of BCSCs. (a) WB showing
PKM2, LDH-A, and G6PDH expression in BCSCs compared with SDACs. b-Actin is used as a protein-loading control. A representative WB of three independent experiments
is shown. (b) PK and (c) LDH, and enzyme activities evaluated in spheres (BCSCs) as compared with differentiated cells (SDACs). Bar graphs show the mean activity (n¼ 6)
expressed as mmol/mgProtein/min, and bars represent the S.E.M. (d) WB showing the expression of PKM2 and LDH-A in cells sorted for CD24 expression. b-Actin is used as a
loading control. (e) PK and (f) LDH activity in CD24 /low cells compared with CD24þ BCSCs. Bar graphs show the mean activity (n¼ 6) expressed as mmol/mgProtein/min,
and bars represent the S.E.M. (g) G6PDH enzyme activity evaluated in spheres (BCSCs) as compared with differentiated cells (SDACs). Bar graphs show the mean activity
(n¼ 6) expressed as mmol/mgProtein/min, and bars represent the S.E.M. (h) NADPþ /NADPH, (i) NADþ /NADH, and (j) ADP/ATP ratios in BCSCs compared with SDACs.
Treatment with rotenone does not affect ATP production in BCSCs, whereas strongly increases the ADP/ATP ratio and inhibits mitochondrial ATP production in SDACs. No
changes in the ADP/ATP ratio are observed in BCSCs and SDACs after addition of dimethylsulphoxide (DMSO) alone used as a vehicle control. Bars show the mean
value±S.D. (n¼ 3). *Po0.050 (unpaired two-tailed t-test or two-factor ANOVA)
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cells are in general highly chemo- and radio-resistant, there is
an urgent need for therapeutic agents to selectively target this
population.2,3 Several signal transduction pathways have
been shown to contribute to the stem-like phenotype and have
been proposed as potential therapeutic targets; moreover,
recent studies indicate that targeting CSC metabolism in
combination with classical chemotherapeutic agents may
provide valuable strategy to eradicate CSCs. Our integrated
proteomic and targeted metabolomic analysis suggest that
BCSCs are more dependent on anaerobic glucose metabo-
lism than more differentiated tumour cells.
Increased glycolytic flux and lactate production even in the
presence of oxygen suggest a switch of BCSC metabolism
from oxidative phosphorylation to aerobic glycolysis, a
phenomenon well known as Warburg effect. Furthermore,
upregulation of aerobic glycolysis has been shown to correlate
with increased tumour aggressiveness and the development
of multi-drug resistance.22,23
Warburg effect has been considered a cellular response to
hypoxic conditions in the tumour microenvironment and the
adaptive overexpression of the transcription factor HIF-1a that
can promote the survival of cancer cells. The higher levels of
HIF-1a in spheres, predicted in silico and effectively observed
in BCSCs even upon normoxic conditions, results in the
increased expression levels of proteins involved in glucose
transport and metabolism as well as lactate production
through the induction of LDH-A, the key enzyme of glucose
fermentation.24 It has been shown that lactate and pyruvate,
found significantly increased in BCSCs, upregulate hypoxia-
inducible genes independently of hypoxia by stimulating the
accumulation of HIF-1a.25 Interestingly, we also found that
BCSCs are enriched in the Krebs cycle intermediate
succinate and show a trend toward increased fumarate
concentration. Succinate and fumarate promote HIF-1a
accumulation through the inhibition of the oxygen-dependent
prolyl hydroxylase domain enzymes that catalyze HIF-1a
degradation, thus providing supporting evidences for
increased HIF-1a in BCSCs upon normoxic conditions.
LDH-A is thought to be a major molecular mediator of the
Warburg effect. LDH-A and LDH-B genes encode for two
protein, namely M and H, respectively, that combine to give
five isoenzymes, which differ in electrophoretic mobility and
Michaelis–Menten constants for lactate and pyruvate. LDH-A,
overexpressed in BCSCs, is associated with the conversion of
pyruvate to lactate, suggesting increased lactic fermentation
in these cells. This hypothesis was supported by the increase
of LDHPyr-Lac activity and lactic acid found in spheres.
Increased local concentration of the toxic lactic acid and
decreased extracellular pH have been recently associated to
the Warburg effect and appear to be advantageous for
invasion and tumourigenesis.26–28
PKM2 is a low activity isoform of PK that promotes the
aerobic glycolysis and contributes to anabolic metabo-
lism.17,29 It is known that PKM2 replaces the normal PK
enzyme in proliferating and tumour cells,30 and a PKM1 (a
highly active PK isoform) to PKM2 isoform switch has been
associated with increased fermentative metabolism,
increased pyruvate and lactate production, and lower oxygen
consumption.17 Notably, PKM2 activity relies on allosteric
activation by fructose 1,6-diphosphate31 and serine.32 The
increased PK activity in the BCSCs is consistent with our data
showing a significant increase of these two allosteric effectors
in BCSCs as compared with SDACs. Furthermore, PK has a
global regulatory role in biosynthetic AA metabolism and
affects the concentration of free AAs.33 In particular, PKM2
upregulation has been shown to stimulate de novo serine
biosynthesis,34 which in turn can allosterically activate PKM2,
consistently with the higher serine levels that we found in
BCSCs. The upregulation of PKM2 and the increase of PK
activity may also correlate with the increase of Arg, Val, and
His that have been previously reported.33 The higher
biosynthesis rate of glucose-derived non-essential AAs linked
to the increase of PK activity suggests that BCSCs divert
glucose-derived carbon into non-ATP-producing pathways
supporting cellular biomass increase.
The increased expression levels and activity of G6PDH and
the increase of ribose 5-phosphate in BCSCs clearly indicates
the activation of the pentose phosphate pathway. These
findings support the idea that BCSCs shift from catabolic
metabolism aimed at energy production toward an anabolic
Figure 5 2-DG induces apoptosis of BCSCs, and its effect is increased by the combination with doxorubicin. (a) BCSCs are treated with doxorubicin (Doxo) and 2-deoxyglycose
(2-DG) alone or the combination of Doxo and 2-DG (Doxoþ 2-DG). Doxo treatment provides cytostatic effect, but cell counts does not significantly differ 24 and 48 h after Doxo
administration (Fischer’s LSD post-hoc test, P¼ 0.768). In contrast, treatment with 2-DG alone decreases BCSCs counts compared with control, 24 h (Fischer’s post-hoc test,
P¼ 0.055) and 48 h (P¼ 8 10 4) Doxo treatment. The treatment with Doxoþ 2-DG significantly decreases cell counts compared with 24 h (P¼ 0.0009) and 48 h
(P¼ 1 10 6) Doxo treatment and 48 h treatment with 2-DG alone (Fischer post-hoc test, P¼ 0.002). Evaluation of apoptosis in (b) BCSCs and (c) SDACs treated for 48 h with
2-DG, Doxo, or a combination of the two. The percentage of hypo-diploid events evaluated by Flow Cytometry after propidium iodide staining is shown
Increase of glycolytic activity in breast cancer stem cells
D Ciavardelli et al
7
Cell Death and Disease
state aimed at supplying biosynthesis precursors, such as
NADPH. According with this hypothesis, the NADP/NADPH
ratio is significantly decreased in spheres, indicating
increased intracellular NADPH levels.
BCSCs also show a high ADP/ATP ratio that may indicate
decreased production of oxidatively derived mitochondrial
ATP, and thus alternative ATP-generating pathways in
BCSCs as well as increased levels of cytosolic ADP, required
to maintain the high rate of glycolysis. Of note, the treatment
with rotenone, amitochondrial complex I inhibitor, significantly
impairs ATP production of cells upon differentiation without
significant effects on BCSCs. Therefore, BCSCs are less
dependent on the mitochondrial activity than normal cancer
cells and rely on aerobic glycolysis for ATP production.
It has been reported that glycolytic cells show low cytosolic
and mitochondrial NADþ /NADH ratios that inhibits the
tricarboxylic acids cycle (TCA) favouring anaerobic glycoly-
sis.35 Furthermore, enhancement of NADþ /NADH levels
inhibits tumourigenesis and metastasis in breast cancer.36
Unexpectedly, BCSCs are characterized by higher NADþ /
NADH level compared with SDACs. This seems to be in
contrast with the aggressive phenotype of this cells and their
tumour-forming ability. However, our data are consistent with
the hypothesis that BCSCs can consume NADH without
producing ATP from mitochondrial electron transport. The
decrease of NADH levels and the corresponding increase of
NADþ /NADH ratio in BCSCs could be related to the increase
of homolactic fermentation rate to regenerate a sufficient
NADþ pool and maintain the high rates of glycolysis,
increasing NADH consumption or to the inhibition of the
TCA cycle. In fact, it is known that increased concentration of
TCA cycle intermediates inhibits the cycle. The increase of
succinate concentration and the trend toward significant
increase of fumarate in BCSCs may partly explain the
increased NADþ /NADH ratio through the inhibition of the
TCA cycle. The strong inhibition of FA beta-oxidation that we
observed in BCSCs provides further evidences of silencing of
mitochondrial activity. Although the exact role of inhibition of
FA oxidative catabolism inhibition is currently unclear, these
preliminary results warrant further investigations.
It is worthy of note that the Warburg effect has been linked to
mitochondrial stability and the cellular redox balance in cancer
cells.37 Promoting glycolysis and limiting mitochondrial activity
may inhibit mitochondrial reactive oxygen species (ROS)
production. It has been recently demonstrated that low levels
of ROS generation through the glycolytic shift contributes to
maintaining a CSC phenotype.9 We found that BCSCs not only
rely on aerobic glycolysis but also strongly overexpress several
antioxidant enzymes such as mitochondrial superoxide dis-
mutase and synthesize more NADPH than differentiated cells.
Increased NADPH biosynthesis may indicate increased source
of reducing equivalents and an improvement of the anti-oxidant
defence through the proxiredoxin, thioredoxin, and glutathione
systems. Of note, it has been recently shown that the key
regulator of aerobic glycolysis PKM2 has a relevant role in
maintaining cellular redox homeostasis allowing greater diver-
sion of glycolytic intermediates into pentose phosphate pathway
and NADPH biosynthesis in response to oxidative stress.38
Therefore it is possible that BCSCs set in motion such
mechanisms to counteract ROS.
Pharmacological targeting of aerobic glycolysis overcomes
the drug resistance of CSCs isolated from several solid
tumours. In particular, it has been shown that inhibition of
glycolysis restores drug sensitivity in high malignant tumour
cells through the inactivation of ABC transporters that provide
the efflux mechanism for chemotherapeutic drugs in CSCs.39
The synthetic glucose analogue, 2-DG is one of the glycolysis
inhibitors that has been shown to inhibit solid tumour growth
and is currently under Phase I/II clinical trials.40,41 Of note, it
has been recently suggested that combination of 2-DG with
widely used chemotherapeutics such as trastuzumab may be
a valuable strategy to overcome drug-resistant BCSCs.42
Here we show that acute treatment with 2-DGhas a significant
cytotoxic effect and induces apoptosis of BCSCs. These
findings are consistent with data showing that 2-DG
significantly affects the ability of CSCs to form spheroids.14
The cytotoxic effect of 2-DG have been previously explained
not only by inhibition of glycolysis and the following metabolic
stress but also by indirect effects on several signalling
pathways such as inhibition of mammalian target of rapamycin
signalling43 or direct effects on pro-apoptotic proteins, such as
Bcl-2 homologous antagonist/killer.44
In contrast, the widely used chemotherapeutic drug Doxo
provides only a cytostatic effect on CSCs and has been shown
to lead to enrichment of cells with CSC characteristics within
the population, thus potentially increasing resistance and risk
of recurrence.45 Interestingly, we found that the combination
of Doxo with 2-DG shows a synergic effect, significantly
enhancing BCSCs’ death in a time-dependent manner.
Moreover, the combined treatment has an important effect
also on more differentiated cancer cells, suggesting that this
combination may target different cancer cell populations.
Doxo is known to increase ROS production, which can
mediate mitochondrial damage and apoptosis in a p53-
independent manner.46,47 It is also known that 2DG treatment
results in increased ROS.48,49 This may provide a rationale for
the enhancement of the effect of Doxo by 2-DG. On the other
hand, combining 2-DG with other drugs may enhance the low
in vivo cytotoxicity of 2-DG40 and overcome the cytostatic
effect of classical chemotherapeutic agents as well. In fact,
targeting aerobic glycolysis with 2-DG markedly overcomes
Doxo resistance of BCSCs, thus providing promising phar-
macological application against BCSCs.
Materials and Methods
Chemicals. All chemicals were supplied by Sigma-Aldrich (Shnelldorf,
Germany) and Fluka (Shnelldorf, Germany) unless otherwise stated.
Tissue collection, isolation, and culture of cancer cells. Human
breast cancer tissues were obtained from patients undergoing surgery in
accordance with the ethical standards of the institutional Committee on Human
Experimentation (authorization no. CE-ISS 09/282). Tumour tissues were
mechanically and enzymatically digested with collagenase (1.5 mg/ml; Gibco Life
Technologies, Grand Island, NY, USA) and hyaluronidase (20 mg/ml) in DMEM
(Gibco), shaking for 1 h at 37 1C. The resulting cell suspension was plated in
ultra-low attachment flasks (Corning Incorporated, Corning, NY, USA) in serum-
free medium supplemented with basic fibroblast growth factor (10 ng/ml) and
epidermal growth factor (20 ng/ml) as previously described.50 This procedure
yielded BCSC lines that were subjected to genotyping to validate each cell line’s
individuality and were further tested for their ability to generate tumour xenografts
that replicated the histology of the parental tumour. To achieve the in vitro
differentiation of BCSCs, dissociated sphere cells were cultured in DMEM for the
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indicated times (3.5 or 7 days) supplemented with 10% fetal bovine serum (FBS)
in adherent conditions. These cells were conventionally indicated as SDACs.18
Cell proliferation assay. Cell viability was determined at 24 and 48 h by
trypan blue dye exclusion assay following the treatment of BCSCs with 35 mmol/l
2-DG as previously reported,14 doxorubicin hydrochloride (1mmol/l), and a
combination of the two drugs at the same concentrations. Control samples were
performed in phosphate-buffered solution (PBS).
Cytofluorimetric analysis. Flow cytometric cellular DNA content evaluation
was performed according to Nicoletti et al.51 Briefly, cells were collected by
trypsinization, pelleted at 800 g for 10 min and fixed in 70% ethanol overnight at
 20 1C. Samples were then washed in PBS and incubated at 37 1C, for 15 min
with a 13 Kunitz units RNAse A solution and for 20 min with 50 mg/ml propidium
iodide. Twenty thousand events were acquired (FACSCanto II Instrument, BD
Biosciences, San Jose, CA, USA) and analysed by using the BD FACSDIVA
software (BD Biosciences).
Flow cytometric analysis of surface markers CD24 and cluster of differentiation
44 (CD44) was performed on 2 105 cells per sample. Cells were washed in PBS,
resuspended in 100ml of specific antibody (antibody-CD24-R-phycoerythrin-
cyanine dye7 (anti-CD24-PE-Cy7), 561646, BD Pharmingen (Franklin Lakes, NJ,
USA); antibody-CD44-allophycocyanin (anti-CD44-APC), 559942, BD Pharmingen)
diluted in 0.5% bovine serum albumin, and incubated for 20 min at room
temperature in the dark. Cell viability solution (555815, BD Biosciences) was used
for detection of non-viable cells according to manufacturer’s protocol. Samples were
then washed and stored at 4 1C in the dark until acquisition. A FACSCantoII flow
cytometer, running with FACSDiVa software (BD Biosciences), was used for sample
acquisition and analysis.
Cell sorting of CD44þ /CD24þ and CD44þ /CD24 /low sub-populations was
performed on single cell suspension from BCSC double stained with anti-CD24-PE-
Cy7 antibody and anti-CD44-APC antibody. Cells were sorted with fluorescence-
activated cell sorting Aria III cell sorter (BD Biosciences). Sub-populations of cells
co-expressing CD44 and CD24 at higher levels or CD24 weak/absent were
collected, and a small amount of cells were re-analysed to check for purity.
Immunoblotting. Cells grown as BCSCs and SDACs were collected by
centrifugation at 1200 revolutions/min. Cell pellets were washed twice with ice-cold
PBS, resuspended in a 50 mmol/l tris(hydroxymethyl)aminomethane (Tris)/HCl
(pH 7.5), 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l NaF, 10% Glycerol (V/V),
1 mmol/l MgCl, 1% Triton X-100 (V/V) ice-cold buffer containing proteinase
inhibitor cocktail and incubated for 30 min on ice. Sample lysates were
centrifugated at 10 000 g for 10 min, and supernatants were collected. Equal
amounts of whole proteins extracts and nuclear extract (B-625 Sigma N-XTRACT,
Shnelldorf, Germany) for HIF-1a immunodetection were resolved on 10% sodium
dodecyl sulphate–polyacrylamide gel electrophoresis gel using a mini-gel
apparatus (GmbH Bio-Rad Laboratories, Hercules CA, USA), transferred onto
polyvinylidene fluoride membranes and subsequently blocked with 5% non-fat dry
milk in PBS/0.1% (V/V) Tween 20. Immunodetection was performed by incubating
the membranes with the different primary antibodies diluted in blocking buffer for
2 h at room temperature or overnight at 4 1C. The following antibodies were used:
anti-LDH (PA5-27406, Thermo Scientific, Rockford, IL, USA), anti-PKM2 (PA-
23034, Thermo Scientific), anti-G6PD (PA5-27359, Thermo Scientific), anti-HIF-1a
(NB100-449, Novus Biologicals, Cambridge, UK), anti-Actin (clone AC-15, A5441
Sigma-Aldrich), and anti-Laminin b (M-20) (sc-6217, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). Immunoreactive bands were visualized with
SuperSignal West Dura Substrate (Pierce Biotechnology, Rockford, IL, USA).
Differential proteomic analysis. Sample preparation, data acquisition
and data processing were performed as previously described.52–54 A total of
100mg of protein extracts from the different conditions in separate experiments
were precipitated with a mix of ethanol, methanol, and acetone (ratio 2 : 1 : 1, V/V)
and then dissolved in 100 mmol/l Tris/HCl pH 7.9 containing 6 M urea and 0.1%
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate and sonicated. The
reduction of proteins was performed by adding 100 mmol/l dithiothreitol (DTT) (1 h
at 36 1C) and 200 mmol/l iodoacetamide (1 h at room temperature). Protein
samples at a final concentration of 2mg/ml were digested with 1 : 20 (w/w)
sequence-grade trypsin (Promega, Madison, WI, USA) at 36 1C overnight. The
reactions were stopped by adding 1 ml of 10% (V/V) trifluoroacetic acid. A total of
0.25mg of the protein digestion was loaded onto the nanoACQUITY UPLC System
(Waters Corporation, Milford, MA, USA) coupled to a quadrupole-time of flight
(Q-Tof) Premier mass spectrometer (Waters Corporation). Before loading, a
digested enolase from Saccharomyces cerevisiae (Waters Corporation) was
added to the sample as internal standard at a final concentration of 200 fmol/l.
Samples were injected onto a Symmetry C18 5 mm, 180 mm 20 mm precolumn
(Waters Corporation) for preconcetration and desalting and were subsequently
separated using a NanoEase BEH C18 1.7mm, 75mm 25 cm nanoscale LC
column (Waters Corporation) maintained at 35 1C. Mobile phase A was water with
0.1% formic acid, and mobile phase B was 0.1% formic acid in acetonitrile.
Peptides were eluted by a gradient of 3–40% mobile phase B over 150 min at a
flow rate of 250 nl/min followed by a gradient of 40–90% mobile phase B over
5-min and a 15-min rinse with 90% mobile phase B. The Q-Tof Premier mass
spectrometer (Waters Corporation) was programmed to step between low (4 eV)
and high (15–40 eV) collision energies using a scan time of 1.5 s over 50–1990 m/
z. Samples from each condition were run at least in triplicate. The best replica for
each condition was used for the subsequent analysis. The Continuum LC-MS data
were processed and searched using ProteinLynx GlobalServer v2.3 (PLGS)
(Waters Corporation). Protein identification was performed using the embedded
ion accounting algorithm of the software and by searching a Uniprot/SWISSProt
human database release 2011_02 (20253 entries), to which the sequence from
the enolase of S. cerevisiae was appended. The parameters for the database
search were as follows: automatic tolerance for precursor ions, automatic
tolerance for product ions, minimum of three fragment ions matched per peptide,
minimum of seven fragment ions matched per protein, minimum of two peptides
matched per protein, one missed cleavage, and carbamidomethylation and
oxidation of methionine as modifications. The false positive rate of the
identification algorithm is typically 3–4% with a randomized database appended
to the original one, which is five times the size of the original utilized database.55,56
The identified proteins displayed in the protein table were normalized against the
P00924 entry (Enolase S. cerevisiae), and peptides from Enolase S. cerevisiae
digestion that were the most reproducible for retention time and intensity deriving
(m/z 807.42, m/z 814.49, m/z 1286.71, m/z 1288.70, m/z 1755.94, m/z 1789.83,
m/z 1840.89) were used to normalize the EMRT table, the list of paired peptide
exact masses and retention time. The list of normalized proteins was screened
according to the following criteria: proteins that were identified in at least two out of
the three injections of the same conditions; proteins with 0oPo0.05 or
0.95oPo1, and proteins with an expression level ratio between the conditions
41.3 on decimal scale. If 0oPo0.05, the likelihood of downregulation is
495%, and if 0.95oPo1 the likelihood of upregulation is 495%. Setting the
threshold of ratio at 1.3 on a decimal scale allowed us to consider the average
relative fold change ±0.30 on a natural log scale. This setting is typically 2–3
times higher than the estimated error of the intensity measurements.56
Targeted metabolomic analysis by GC–MS. GC–MS analysis of cell
lysates was performed as previously described.57 Briefly, cell samples
(approximately 1.5 106 cells) were extracted with a solution of ethanol/water
(50ml, 80 : 20, V:V), and cell homogenate (50 ml) were precipitated with 100ml of
cold 0.1% (V/V) methanolic trichloroacetic acid immediately after homogenization.
Internal standards (13C4 malic acid,
13C4 succinic acid,
13C6 glucose; IS) were then
added to give a final concentration of 10mg/ml. Samples were centrifuged at
10 000 g for 30 min, and supernatants were collected and dried in a SpeedVac
system (ThermoSavant, Waltham, MA, USA). The dried extracts were derivatized
with 20ml of 20 mg/ml of methoxyamine hydrochloride solution in pyridine for
60 min at 70 1C followed by reaction with 20ml of N,O-bis(trimethylsilyl)trifluor-
oacetamide with 1% of trimethylchlorosilane for 60 min at 70 1C. GC–MS analysis
was performed using a 6890N gas-chromatograph equipped with a 7863 Series
auto-sampler and coupled with a 5973N mass spectrometer (Agilent Technologies,
Palo Alto, CA, USA) operating in electron impact ionization mode. Three
microlitres were injected in pulsed-splitless mode by applying a pressure of 80 psi.
The injector temperature was kept at 250 1C. Chromatographic separations were
obtained using a fused silica capillary column HP-5MS (30 m x 0.25 mm, Agilent
Technologies). Helium was used as carrier gas at a constant flow rate of 1 ml/min.
The GC oven was programmed as follows: start at 70 1C (hold time 1 min), which
was raised at 4 1C/min to 300 1C (hold time 5 min). The mass spectrometer was
automatically calibrated using per-fluoro tributylamine as calibration standard. For
quantification, the mass spectrometer was used in the selective ion monitoring
mode, and mass spectra were recorded in positive modes by monitoring the
following ions: m/z 174 (pyruvic acid; IS: 13C3 pyruvic acid, m/z 177), m/z 147
(lactic acid; IS: 13C4 succinic acid, m/z 251), m/z 247 (succinic acid; IS:
13C4
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succinate, m/z 251), m/z 245 (fumaric acid; IS: 13C4 malic acid, m/z 236), m/z 233
(malic acid; IS: 13C4 malic acid, m/z 236); m/z 328 (glyceraldheyde 3-phosphate;
IS: 13C4 malic acid, m/z 236), m/z 357 (3-phosphoglyceric acid; IS:
13C4 malic acid,
m/z 236), m/z 375 (citric acid; IS: 13C4 malic acid, m/z 236), m/z 319 (glucose; IS:
13C6 glucose, m/z 323), m/z 387 (glucose 6-phosphate; IS:
13C6 glucose, m/z
323), and m/z 459 (fructose 1,6-diphosphate; IS: 13C6 fructose 1,6-diphosphate,
m/z 462). Mass spectrometer operating parameters were: interface temperature
300 1C, ion source 250 1C, and quadrupole 150 1C. The external standard method
and internal standard correction were applied for quantification of target
metabolites. Data acquisition was performed using the G1701CA ChemStation
software (Agilent Technologies).
Determination AAs and AcCs. AA and AcCs analysis was performed by
LC-MS/MS as previously described.58,59 Cell samples (approximately 1.5 106
cells) were extracted with a solution of Ethanol/Water (50ml, 80 : 20, V:V). The
samples were then sonicated and centrifuged (15 600 r.p.m. at 4 1C for 20 min),
and the supernatant was recovered. The lysate (7ml) were added to 100ml of the
stable isotope-labeled IS obtained from the NeoBase Non-derivatized MSMS Kit
(Perkin Elmer Life and Analytical Sciences, Turku, Finland). The sample were
analysed by direct infusion mass spectrometry using a LC-MS/MS system
consisting of an Alliance HT 2795 HPLC Separation Module coupled to a Quattro
Ultima Pt ESI tandem quadrupole mass spectrometer (Waters Corporation). The
instrument was operated in positive electrospray ionization mode using MassLynx
V4.0 Software (Waters Corporation). A detailed description of electrospray
ionization mass spectrometry acquisition parameters are available in
Supplementary Table S6. Auto data processing was performed using the
NeoLynx (Waters Corporation) software.
Pyruvate kinase activity. PK activity was measured by converting the
product pyruvate into lactate using LDH, with a concomitant conversion of NADH
to NADþ , resulting in a decrease in absorbance at 340 nm.60 In all, 7 106 cells
were lysed in 200ml of buffer containing 10 mmol/l Tris–HCl (pH 7.5), 1.5 mmol/l
MgCl2, 20 mmol/l NaCl, 1 mmol/l DTT, 1 mmol/l phenylmethylsulfonyl fluoride, and
protease inhibitor cocktail. After two centrifugations at 17 000 g for 30 min each,
PK activity was measured in the supernatant by a LDH-coupled assay. The 200-ml
reaction mixture was prepared on ice containing 100 mmol/l Tris–HCl (pH 8.0),
100 mmol/l KCl, 10 mmol/l MgCl2, 0.5 mmol/l EDTA, 0.2 mmol/l NADH, 1.5 mmol/l
ADP, 5 mm phosphoenolpyruvate, and 200 units/ml LDH. The reaction was
initiated by the addition of 0.7mg of total cell extract. PK activity was calculated at
37 1C by monitoring the absorbance at 340 nm every 30 s for 5 min in an
microplate reader (Spectra max 190, Molecular Devices, Sunnyvale, CA, USA).
A unit of PK activity is defined here as the amount of enzyme required to oxidize
1mmol of NADH per minute under these experimental conditions.
LDH activity. Direct LDH activity (LDHPyr-Lac) was spectrometrically assayed
as previously described61,62 using a tunable microplate reader (Spectra max 190,
Molecular Devices). Briefly, cell pellets were lysed in 0.010 mol/l PBS (20 ml/g of
pellet, wet weight; pH¼ 7.4). Cell lysates were centrifuged at 2000 g for 3 min
at 4 1C to remove cell debris. Supernatants were further centrifuged 8000 g for
10 min at 4 1C in order to obtain cytosolic fractions. Protein concentration was
determined according to the Bradford assay.63 Therefore, pyruvate (25 ml, 2.50 g/l)
and NADH (100ml, 0.3 g/l) were added to the samples (10ml corresponding
to 0.5mg of total proteins) and the decrease of absorbance at 340 nm
was measured at 37 1C every 30 s for 5 min. LDHPyr-Lac activity is expressed
as mmol/mgprotein/min.
G6PDH activity. G6PDH was assayed using a tunable microplate reader
(Spectra max 190, Molecular Devices), according to the spectrophotometric
methods previously described64 with minor modifications. Cell pellets were
homogenized, and protein quantification were performed as described for LDH
activity assay. To measure G6PDH activity, the sample (10 ml corresponding to
0.5mg of total proteins) was added to a solution containing glucose 6-phosphate
(0.2 mmol/l), NADPþ (0.1 mmol/l), Tris/HCl buffer (50 mmol/l, pH¼ 8.1), and
MgCl2 (1 mmol/l). The final volume was 150ml. The increase of absorbance at
340 nm was measured every 30 s for 5 min at 37 1C. G6PDH activity was
expressed as mmol/mg protein/min.
NADþ /NADH and NADPþ /NADPH determination. NADþ /NADH
ratio were measured by a ultrasensitive colorimetric assay (EnzyChrom
NADþ /NADH Assay Kit (E2ND-100), BioAssay Systems, Hayword, CA, USA)
according to the manufacturer’s instructions. This assay is based on a LDH cycling
reaction.65 Briefly, cells were lysed with either 100ml NADþ extraction buffer for
NADþ determination or 100 ml NADH extraction buffer for NADH determination.
After heating at 60 1C for 5 min, 20ml of assay buffer and 100ml of the opposite
extraction buffers (NADH extraction buffer or NADþ extraction buffer,
respectively) were added. The samples were then centrifuged at 14 000 r.p.m.
for 5 min, and the supernatants (40ml) were used for NADþ /NADH assays. The
optical density (OD) was read at 565 nm in a tunable microplate reader (Spectra
max 190, Molecular Devices) for time 0 and after 15 min. NADþ and NADH
concentrations were measured as: (DOD-b0)/b1, where b0 and b1 are the
intercept and slope of the external calibration curve.
NADPþ /NADPH ratio were measured by a ultrasensitive colorimetric assay
(EnzyChrom NADPþ /NADPH Assay Kit (ECNP-100), BioAssay Sistems) following
the manufacturer’s instructions. This assay is based on a glucose dehydrogenase
cycling reaction.65 The absorbance was measured at 565 nm using a tunable
microplate reader (Spectra max 190, Molecular Devices), and the same procedure
applied for NADþ /NADH determination was performed. All analysis were
performed in triplicate.
ADP/ATP ratio determination. ADP/ATP ratio was measured based on
luciferin–luciferase reaction using Enzylight ADP/ATP ratio assay kit (ELDY-100)
(BioAssay Systems) following the manufacturer’s instructions. Briefly, BCSCs
cells were seeded in a 96-well flat-bottom plate and incubated for 3 days to allow
for cell differentiation and recovery (1 104 cells at 100 ml per well). BCSCs
(1 104 cells) were treated with the assay buffer (90 ml) containing luciferin–
luciferase. After 1 min, luminescence (relative light units (RLU) A) was recorded
by Lumat LB 9507 Ultra Sensitive Tube Luminometer (Berthold Technologies,
Oak Ridge, TN, USA). The luminescence was read also after 10 min (RLU B).
This measurement provided background before measuring ADP. Therefore, 5 ml
ADP reagent was added to each well, and after 1 min, luminescence (RLU C)
was obtained. ADP/ATP ratio was measured as: (RLU CRLU B)/RLU A. All
analysis were performed in triplicate. The same procedure was applied for the
measurement of ADP/ATP ratio in BCSCs and SDACs following treatment with
rotenone (50 mmol/l) for 60 min.
Statistical and bioinformatic analysis. Differences between the
protein expression levels, enzymatic activities, and metabolite concentrations
in BCSCs and SDACs were assessed by unpaired two-tailed t-test. Two-factor
ANOVA followed by Fisher’s least significant difference (LSD) post-hoc test was
performed in order to assess the significance of the treatment effects. Data
were ranked and aligned where Levene test failed to show homoscedasticity.
Aligned rank transformation (ART) of data was performed using the ART web
software available at http://faculty.washington.edu/aimgroup/proj/art/artweb/.66
Treatment (PBS, Doxo, 2-DG, and Doxoþ 2-DG) and the treatment time (24 or
48 h) were the independent factors. P-values o0.050 were considered
statistically significant. Statistical analysis was performed using the Statistica
6.0 (StatSoft Inc., Tulsa, OK), XLStat2007.1 (Microsoft, Redmond, WA, USA)
and Microsoft Excel software.
Protein network analysis was performed using the Ingenuity Pathway Analysis
(IPA) application (Ingenuity System, http://www.ingenuity.com). IPA constructs
hypothetical protein interaction clusters on the basis of the Ingenuity Pathways
Knowledge Base. Direct and indirect relationships between the identified proteins
were shown as networks on the base of all genes, and endogenous chemicals
present in the Ingenuity Knowledge Network scores are calculated as  log
(P-value) and indicate the likelihood that focus genes (i.e., the identified proteins
within a specific network) are clustered together. Biological functions and canonical
pathways over-represented among the identified proteins were also assigned to
networks stored in the Ingenuity Pathways Knowledge Base. Biological functions
and canonical pathways were ranked in accordance to their significance.
Significance was evaluated by exact Fisher’s test. A P-value of 0.01 corresponding
to a score of 2 was considered the cutoff for the analysis.
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